Royalty Report: Drugs, Biotechnology, Drug Discovery – Collection: 29276

$100.00

Curated Royalty Rate Report
Created On: 2020-07-15, Record Count: 4

Description

This collection of transactions and supporting information was developed using our AI algorithm to curate similar royalty reports into a cohesive collection to support your licensing, transfer pricing or other transaction scenarios where documented royalty rates and/or deal terms are important.
Created On: 2020-07-15
Record Count: 4

Primary Industries

  • Drugs
  • Biotechnology
  • Drug Discovery
  • Delivery
  • Disease
  • Therapeutic

IPSCIO Report Record List

Below you will find the records curated into this collection.  This summary includes the complete licensed property description so that you can review and determine if this collection covers the topics, technology or transaction type that is relevant for your needs.  The full report will include all relevant deal data such as the royalty base, agreement date, term description, royalty rates and other deal terms.  For reference, here is a sample of a full IPSCIO curated royalty rate report: Sample Report

IPSCIO Record ID: 29276

License Grant
The Licensor grants Optionee, an exclusive option to acquire an exclusive, worldwide License to practice Patent Rights and Technology Rights in all therapeutic applications, with a right to subLicense. Patent Rights mean the Licensor's rights in information or discoveries covered by U.S. Patent Application entitled Covalent and non-covalent chemically modified polynucleotide complexes for in vivo delivery and Technology Rights means the Licensor's rights in any technical information, know-how, process, procedure, composition, method, formula, protocol, technique or data developed by Anastasia Khvorova, Ph.D. at Licensor prior to the effective date relating to technology which are not covered by Patent Rights, but which are necessary for practicing the invention covered by Patent Rights.
License Property
The RNAi delivery technologies encompass four distinct approaches, primarily focusing on self-delivery, i.e., RNAi delivery without the use of a separate transport vehicle. Upon evaluating the Advirna technology, RXi observed that it delivers RNAi molecules to cells spontaneously upon direct administration, both in vitro and in vivo, without requiring a delivery vehicle or transfection formulation. RXi has reproduced this result in many cells, even in those that are difficult to transfect.
Field of Use
The rights apply in all therapeutic applications.

IPSCIO Record ID: 823

License Grant
Licensor hereby assigns, transfers and conveys to Licensee all of Licensor's rights, titles, and interests throughout the territory in and to the Patent Rights and Technology Rights, and further, all rights and privileges pertaining to the Patent Rights and Technology Rights, including, without limitation, the right, if any, to sue or bring and recover for, and the right to profits or damages due or accrued, arising out of or in connection with, any and all actions for past, present and future infringement thereof.
License Property
Patent Rights mean any Licensor rights to pending or issued patent claims supported by U.S. Patent Application No. 61/192,954 (the ‘954 application), entitled Chemically modified polynucleotides and methods of using the same, and any patent application related or claiming priority to the ‘954 application.

As part of the transactions contemplated by the contribution and securities purchase Agreements the Licensee entered into a related party agreement with the Licensor.

The Licensee has agreed to issue to the Licensor, upon the completion of the spin-off transaction, shares of our common stock equal to approximately 5% of the fully diluted shares of RXi common stock assuming the conversion in full of all outstanding Series A Preferred Stock.

Anastasia Khvorova, Ph.D., our Senior Vice President and Chief Scientific Officer, is a director and 50% owner of the Licensor. Dr. Khvorova’s husband is the other director and 50% owner of the Licensor.

Field of Use
The Licensor assigned the Licensee its existing patent and technology rights related to sd-rxRNA technology in exchange for the Licensee Agreement to pay the Licensor an annual maintenance fee and a one-time milestone payment upon the future issuance of the first patent with valid claims covering the assigned patent and technology rights.

The Licensee has granted back to the Licensor a License under the assigned patent and technology for fields of use outside the fields of human therapeutics and diagnostics.

IPSCIO Record ID: 289256

License Grant
Licensor will grant to Canadian Licensee a non-exclusive license to any Licensor Intellectual Property for use in RNAi Products.
License Property
Licensed Product means any product, good, or service covered by a claim of the Licensor controlled Intellectual Property or Licensee controlled Intellectual Property.

RNAi Product means a product containing, comprised of or based on siRNA, Dicer Substrates, Multivalent RNA, or any derivatives thereof, which are effective in gene function modulation and designed to modulate the function of particular genes or gene products by causing degradation through RNA interference of a Target mRNA to which such siRNAs or siRNA derivatives or moieties are complementary. For greater clarity, an RNAi Product shall not include Antisense.

RNAi (RNA interference) is a revolution in biology, representing a breakthrough in understanding how genes are turned on and off in cells, and a completely new approach to drug discovery and development. Its discovery has been heralded as “a major scientific breakthrough that happens once every decade or so,” and represents one of the most promising and rapidly advancing frontiers in biology and drug discovery today which was awarded the 2006 Nobel Prize for Physiology or Medicine. RNAi is a natural process of gene silencing that occurs in organisms ranging from plants to mammals.

LNP intellectual property for use in RNAi therapeutic products using LNP technology.

LNP technology relates to where RNAi therapeutics have the potential to treat a broad number of human diseases by “silencing” disease causing genes. RNAi therapeutics, such as “siRNAs,” require delivery technology to be effective systemically. LNP technology represents the most widely adopted delivery technology for the systemic delivery of RNAi therapeutics. Licensor’s LNP platform is being utilized in multiple clinical trials.  LNP technology encapsulates siRNAs with high efficiency in uniform lipid nanoparticles that are effective in delivering RNAi therapeutics to disease sites in numerous preclinical models.

siRNA means a double-stranded ribonucleic acid (RNA) composition designed to act primarily through an RNA interference mechanism that consists of either (a) two separate oligomers of native or chemically modified RNA that are hybridized to one another along a substantial portion of their lengths, or (b) a single oligomer of native or chemically modified RNA that is hybridized to itself by self-complementary base-pairing along a substantial portion of its length to form a hairpin.

Supplemental Field Product means a product containing, comprised of, or based on Antisense or Gene Therapy.

Intellectual Property means any and all discoveries, inventions, information, knowledge, know-how, trade secrets, designs, practices, methods, uses, compositions of matter, articles of manufacture, protocols, formulas, processes, assays, skills, experience, techniques, data, reports, and results of experimentation and testing and other scientific or technical information, patentable or otherwise, controlled by a party after the Effective Date.

Field of Use
Field of Use means the delivery of an RNAi Product for any and all purposes.

Supplemental Field means the delivery of (i) single-stranded oligonucleotides, either chemically modified or unmodified, acting through the RNase H mechanism or by or other mechanisms of translational arrest but excluding RNA interference involving RISC (“Antisense”) and (ii) DNA plasmids or messenger RNA (mRNA) either chemically modified or unmodified that are transcribed and/or translated into protein and wherein the pharmacological activity is dependent on expression of the protein (Gene Therapy).

IPSCIO Record ID: 289255

License Grant
For the LNP Technology, Canadian Licensor will grant to Licensee a non-exclusive right to use the Licensor Combined Licensed Technology and the Category 1 Patents for use in developing and commercializing Supplemental Field Products. The license granted to Licensee supersedes and replaces the licenses granted to Licensee by Party A and Licensor in the current Supplemental Agreement. Licensee’s right to sub-license will be on a Sublicensable Product-by-Sublicensable Product basis.
License Property
Licensed Product means any product, good, or service covered by a claim of the Licensor controlled Intellectual Property or Licensee controlled Intellectual Property.

LNP intellectual property for use in RNAi therapeutic products using LNP technology.

LNP technology relates to where RNAi therapeutics have the potential to treat a broad number of human diseases by “silencing” disease causing genes. RNAi therapeutics, such as “siRNAs,” require delivery technology to be effective systemically. LNP technology represents the most widely adopted delivery technology for the systemic delivery of RNAi therapeutics. Licensor’s LNP platform is being utilized in multiple clinical trials.  LNP technology encapsulates siRNAs with high efficiency in uniform lipid nanoparticles that are effective in delivering RNAi therapeutics to disease sites in numerous preclinical models.

RNAi Product means a product containing, comprised of or based on siRNA, Dicer Substrates, Multivalent RNA, or any derivatives thereof, which are effective in gene function modulation and designed to modulate the function of particular genes or gene products by causing degradation through RNA interference of a Target mRNA to which such siRNAs or siRNA derivatives or moieties are complementary. For greater clarity, an RNAi Product shall not include Antisense.

siRNA means a double-stranded ribonucleic acid (RNA) composition designed to act primarily through an RNA interference mechanism that consists of either (a) two separate oligomers of native or chemically modified RNA that are hybridized to one another along a substantial portion of their lengths, or (b) a single oligomer of native or chemically modified RNA that is hybridized to itself by self-complementary base-pairing along a substantial portion of its length to form a hairpin.

Supplemental Field Product means a product containing, comprised of, or based on Antisense or Gene Therapy.

Intellectual Property means any and all discoveries, inventions, information, knowledge, know-how, trade secrets, designs, practices, methods, uses, compositions of matter, articles of manufacture, protocols, formulas, processes, assays, skills, experience, techniques, data, reports, and results of experimentation and testing and other scientific or technical information, patentable or otherwise, controlled by a party after the Effective Date.

RNAi (RNA interference) is a revolution in biology, representing a breakthrough in understanding how genes are turned on and off in cells, and a completely new approach to drug discovery and development. Its discovery has been heralded as “a major scientific breakthrough that happens once every decade or so,” and represents one of the most promising and rapidly advancing frontiers in biology and drug discovery. RNAi is a natural process of gene silencing that occurs in organisms ranging from plants to mammals.

Field of Use
Field of Use means the delivery of an RNAi Product for any and all purposes.

Supplemental Field means the delivery of (i) single-stranded oligonucleotides, either chemically modified or unmodified, acting through the RNase H mechanism or by or other mechanisms of translational arrest but excluding RNA interference involving RISC (“Antisense”) and (ii) DNA plasmids or messenger RNA (mRNA) either chemically modified or unmodified that are transcribed and/or translated into protein and wherein the pharmacological activity is dependent on expression of the protein (Gene Therapy).

Disclaimer: The information gathered from RoyaltySource® database was sourced from the U.S. Securities and Exchange Commission EDGAR Filings and other public records. While we believe the sources to be reliable, this does not guarantee the accuracy or completeness of the information provided. Further, the information is supplied as general guidance and is not intended to represent or be a substitute for a detailed analysis or professional judgment. This information is for private use only and may not be resold or reproduced without permission.